[go: up one dir, main page]

DK2344471T3 - 7-piperidinalkyl-3,4-dihydroquinolon-derivat - Google Patents

7-piperidinalkyl-3,4-dihydroquinolon-derivat

Info

Publication number
DK2344471T3
DK2344471T3 DK09817928.6T DK09817928T DK2344471T3 DK 2344471 T3 DK2344471 T3 DK 2344471T3 DK 09817928 T DK09817928 T DK 09817928T DK 2344471 T3 DK2344471 T3 DK 2344471T3
Authority
DK
Denmark
Prior art keywords
piperidinealkyl
dihydroquinolone
derivative
dihydroquinolone derivative
Prior art date
Application number
DK09817928.6T
Other languages
English (en)
Inventor
Kosuke Kanuma
Naoki Miyakoshi
Madoka Kawamura
Tsuyoshi Shibata
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK2344471T3 publication Critical patent/DK2344471T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK09817928.6T 2008-10-02 2009-09-30 7-piperidinalkyl-3,4-dihydroquinolon-derivat DK2344471T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008257072 2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en) 2008-10-02 2009-09-30 7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number Publication Date
DK2344471T3 true DK2344471T3 (da) 2013-10-07

Family

ID=42073652

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09817928.6T DK2344471T3 (da) 2008-10-02 2009-09-30 7-piperidinalkyl-3,4-dihydroquinolon-derivat

Country Status (28)

Country Link
US (1) US8461182B2 (da)
EP (1) EP2344471B1 (da)
JP (1) JP5541279B2 (da)
KR (1) KR20110067026A (da)
CN (1) CN102239159B (da)
AR (1) AR073727A1 (da)
AU (1) AU2009300607C1 (da)
BR (1) BRPI0925343A2 (da)
CA (1) CA2739513A1 (da)
CL (1) CL2011000734A1 (da)
CO (1) CO6321164A2 (da)
CY (1) CY1114165T1 (da)
DK (1) DK2344471T3 (da)
ES (1) ES2424393T3 (da)
HR (1) HRP20130728T1 (da)
IL (1) IL212070A (da)
MX (1) MX2011003500A (da)
MY (1) MY154337A (da)
NZ (1) NZ592008A (da)
PE (1) PE20110410A1 (da)
PL (1) PL2344471T3 (da)
PT (1) PT2344471E (da)
RS (1) RS52964B (da)
RU (1) RU2498981C2 (da)
SI (1) SI2344471T1 (da)
UA (1) UA105187C2 (da)
WO (1) WO2010038901A1 (da)
ZA (1) ZA201102315B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011219467A (ja) * 2010-03-26 2011-11-04 Taisho Pharmaceutical Co Ltd 7−ピペリジノアルキル−3,4−ジヒドロキノロン誘導体を含有する医薬
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
CA2871514C (en) 2012-05-08 2020-08-25 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ror.gamma.activity and the treatment of disease
CN105228604A (zh) * 2013-03-12 2016-01-06 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
EP3110429A4 (en) 2014-02-27 2018-02-21 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. RORγT阻害剤としての置換ピラゾール化合物及びその使用
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションLycera Corporation RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
MD3413892T2 (ro) * 2016-02-12 2022-06-30 Cytokinetics Inc Derivați de tetrahidroizochinolină

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR003996A1 (es) * 1995-09-15 1998-09-30 Sanofi Aventis Compuestos derivados de quinolein-2 (1h)-ona, procedimiento de preparacion de dichos compuestos y medicamento y composicion farmaceutica que los contienen.
AU2002334733B2 (en) 2001-10-01 2006-11-23 Arena Pharmaceuticals, Inc. MCH receptors antagonists
KR20040048995A (ko) * 2001-10-25 2004-06-10 다케다 야쿠힌 고교 가부시키가이샤 퀴놀린 화합물
EP1464335A3 (en) 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
JP2006522109A (ja) 2003-03-31 2006-09-28 大正製薬株式会社 新規なキナゾリン誘導体及びそれらの使用に関連する治療方法
US20050209274A1 (en) 2004-02-26 2005-09-22 Lynch John K Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
NZ549673A (en) 2004-03-30 2010-03-26 Taisho Pharmaceutical Co Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
JP2008514546A (ja) 2004-09-30 2008-05-08 大正製薬株式会社 ピリジン誘導体及びその使用に関連する治療法
CA2666084A1 (en) 2006-10-06 2008-04-17 Taisho Pharmaceutical Co., Ltd. 1-naphthyl alkylpiperidine derivative

Also Published As

Publication number Publication date
KR20110067026A (ko) 2011-06-20
IL212070A0 (en) 2011-06-30
AU2009300607A1 (en) 2010-04-08
EP2344471A1 (en) 2011-07-20
AR073727A1 (es) 2010-11-24
CO6321164A2 (es) 2011-09-20
RS52964B (sr) 2014-02-28
MY154337A (en) 2015-05-29
PE20110410A1 (es) 2011-07-02
CA2739513A1 (en) 2010-04-08
EP2344471A4 (en) 2012-05-30
AU2009300607B2 (en) 2014-02-27
US8461182B2 (en) 2013-06-11
PT2344471E (pt) 2013-08-01
NZ592008A (en) 2011-12-22
US20110178304A1 (en) 2011-07-21
IL212070A (en) 2014-07-31
CN102239159B (zh) 2014-06-25
CY1114165T1 (el) 2016-08-31
RU2498981C2 (ru) 2013-11-20
ZA201102315B (en) 2012-06-27
WO2010038901A1 (en) 2010-04-08
BRPI0925343A2 (pt) 2015-07-28
AU2009300607C1 (en) 2014-08-07
HRP20130728T1 (en) 2013-10-11
JP5541279B2 (ja) 2014-07-09
HK1159622A1 (en) 2012-08-03
EP2344471B1 (en) 2013-07-24
MX2011003500A (es) 2011-05-02
PL2344471T3 (pl) 2013-12-31
CN102239159A (zh) 2011-11-09
SI2344471T1 (sl) 2013-11-29
CL2011000734A1 (es) 2011-09-23
ES2424393T3 (es) 2013-10-01
UA105187C2 (uk) 2014-04-25
RU2011117161A (ru) 2012-11-10
JP2012504549A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
NO2021006I1 (no) Quofenix, delafloksacin
DK2344471T3 (da) 7-piperidinalkyl-3,4-dihydroquinolon-derivat
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINDERIVAT
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
EP2336132A4 (en) MORPHOLINPURINDERIVAT
EP2320913A4 (en) NUCLEIC ACID APTAMERS
UY33125A (es) Diaza-espiro-[5,5]-undecanos
DK2275414T3 (da) Cyclopentylacrylamidderivat
FI8206U1 (fi) Kanylointisimulantti
EP2377648A4 (en) GRINDING MACHINE INNER TOOTH WHEEL
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
EP2360457A4 (en) Gas shutoff device
EP2318641A4 (en) TOOL FOR CENTERING FOR DRILLING ENCLOSURE
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0912716A2 (pt) composto.
BRPI0909425A2 (pt) derivado de hidroxiquinoxalinacarboxamida